Novartis (India)

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Iain B. McInnes, Philip J. Mease, Bruce Kirkham et al. · The Lancet · 2015 · 827 citations

Inflammation, Rheumatology, Autoimmune Disease +8

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

Jens Kühle, Harald Kropshofer, Dieter Haering et al. · Neurology · 2019 · 531 citations · Full text

Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study

Stephen J. Schuster, Constantine S. Tam, Peter Borchmann et al. · The Lancet Oncology · 2021 · 528 citations

Hematological Malignancy, Lymphoid Neoplasia, Medicine +8

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Reinhard Dummer, Axel Hauschild, Mario Santinami et al. · New England Journal of Medicine · 2020 · 397 citations · Full text

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase

Marcus Maurer, Sabine Altrichter, Thomas Bieber et al. · Journal of Allergy and Clinical Immunology · 2011 · 354 citations

Allergy, Autoimmune Disease, Allergy Medicine +8